NewBiologix Unleashes the Power of Xcell™ Portfolio
In the realm of gene and cell therapy, innovation is crucial for addressing the escalating demands of production and quality assurance. NewBiologix, a leading technology innovation company, has recently launched the Xcell™ Portfolio, aimed at transforming the manufacturing landscape for viral vectors crucial in gene therapies. This comprehensive suite of advanced technologies is poised to streamline production processes, enhance reliability, and ensure scalability.
Meeting Industry Challenges with Advanced Solutions
The challenges facing gene therapy production, including low yield rates, batch inconsistencies, and high costs, are barriers that many companies encounter. The Xcell Portfolio is designed specifically to tackle these issues, providing deeper insights and thorough analysis of rAAV (recombinant adeno-associated virus) quality, which has historically presented hurdles for researchers and manufacturers.
Innovative Technologies at Play
The Xcell Portfolio boasts a variety of cutting-edge solutions:
- Xcell™ Eng-HEK293 Cell Line: This engineered high-performance HEK293 cell line is tailored for effective transient rAAV production, optimizing yield and reducing complexities.
- Xcell™ rAAV Production & Testing Platform: Designed to refine the production and testing processes, this platform accelerates development timelines and improves the overall quality of rAAV candidates.
- Xcell™ Genomic Analytical Platform: Offering specialized sequencing and comprehensive bioinformatics, this platform is adept at addressing diverse scientific inquiries, ensuring robustness in research outcomes.
Commitment to Advancement in Gene Therapy
According to Igor Fisch, Ph.D. and CEO of NewBiologix, "The innovative Xcell Portfolio draws from our leadership’s extensive experience in cell line development, with a keen focus on precision and scalability. Our mission is clear: to accelerate rAAV development for research institutions and industry stakeholders alike, facilitating the delivery of safe and effective gene therapies to patients in need."
Déborah Ley, Ph.D. and Chief Operating Officer, adds, "With our Xcell Portfolio, we're looking forward to collaborating with leading gene therapy companies to unlock new therapeutic potential and expedite the production of rAAVs." This commitment not only underscores NewBiologix's strategic goals but also highlights its intent to lead in innovation within the industry.
About NewBiologix SA
NewBiologix SA is at the forefront of biotechnology, specializing in Swiss-engineered solutions and technologies that enhance the production of cell and gene therapies. With a profound focus on cell line engineering, the company aims to eliminate barriers to production, enabling faster and safer gene therapy deployment. Through its advanced cell line offerings and dedicated platform services, NewBiologix is helping to reimagine the future of patient health.
Frequently Asked Questions
What is the Xcell™ Portfolio launched by NewBiologix?
The Xcell™ Portfolio consists of advanced technologies designed to enhance the efficiency, scalability, and reliability of gene therapy production.
What challenges does the Xcell™ Portfolio aim to address?
The portfolio tackles issues such as low yields, batch heterogeneity, scalability, and high production costs in gene therapy manufacturing.
Who leads NewBiologix?
NewBiologix is led by CEO Igor Fisch, Ph.D., who focuses on innovation and excellence in gene therapy production.
What products are included in the Xcell™ Portfolio?
The Xcell™ Portfolio includes the Xcell™ Eng-HEK293 Cell Line, Xcell™ rAAV Production & Testing Platform, and Xcell™ Genomic Analytical Platform.
How does NewBiologix contribute to patient health?
By providing innovative solutions in gene therapy production, NewBiologix enables faster and safer treatments, ultimately improving patient health outcomes.
